title: Chronic Δ⁹-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques.
abstract: Persons living with HIV/AIDS (PLWHA) frequently use cannabinoids, either recreationally by smoking marijuana or therapeutically (delta-9-tetrahydrocannabinol; Δ(9)-THC dronabinol). Previously, we demonstrated that chronic Δ(9)-THC administration decreases early mortality in male simian immunodeficiency virus (SIV)-infected macaques. In this study, we sought to examine whether similar protective effects resulted from chronic cannabinoid administration in SIV-infected female rhesus macaques. Clinical and viral parameters were evaluated in eight female rhesus macaques that received either Δ(9)-THC (0.18-0.32 mg/kg, intramuscularly, twice daily) or vehicle (VEH) starting 28 days prior to intravenous inoculation with SIVmac251. SIV disease progression was assessed by changes in body weight, mortality, viral levels in plasma and mucosal sites, and lymphocyte subsets. In contrast to our results in male animals, chronic Δ(9)-THC did not protect SIV-infected female rhesus macaques from early mortality. Markers of SIV disease, including viral load and CD4(+)/CD8(+) ratio, were not altered by Δ(9)-THC compared to control females; however, females that received chronic Δ(9)-THC did not gain as much weight as control animals. In addition, Δ(9)-THC administration increased total CXCR4 expression in both peripheral and duodenal CD4(+) and CD8(+) T lymphocytes prior to SIV inoculation. Although protection from early mortality was not evident, chronic Δ(9)-THC did not affect clinical markers of SIV disease progression. The contrasting effects of chronic Δ(9)-THC in males versus females remain to be explained, but highlight the need for further studies to explore the sex-dependent effects of Δ(9)-THC and other cannabinoids on the HIV disease course and their implications for virus transmission.
authors.affiliation: Departments of Physiology, Pharmacology, and Microbiology, Immunology, & Parasitology and the Alcohol and Drug Abuse Center of Excellence, Louisiana State University Health Sciences Center , New Orleans, Louisiana.
authors.forename: Angela M
authors.initials: AM
authors.lastname: Amedee
authors.forename: Whitney A
authors.initials: WA
authors.lastname: Nichols
authors.forename: Nicole J
authors.initials: NJ
authors.lastname: LeCapitaine
authors.forename: Curtis Vande
authors.initials: CV
authors.lastname: Stouwe
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Birke
authors.forename: Nedra
authors.initials: N
authors.lastname: Lacour
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Winsauer
authors.forename: Patricia E
authors.initials: PE
authors.lastname: Molina
mesh_terms: D000818:Animals; D016516:CD4-CD8 Ratio; D018450:Disease Progression; D013759:Dronabinol / Q000627:therapeutic use*; D005260:Female; D008253:Macaca mulatta; D008597:Menstrual Cycle / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000096:biosynthesis; D016097:Simian Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality; D019562:Viral Load / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019718:Receptors, CXCR4; D013759:Dronabinol
references.citation: J Neuroimmune Pharmacol. 2013 Jun;8(3):608-20
references.pmid: 23471521
references.citation: Physiol Behav. 1975 May;14(5):579-87
references.pmid: 1135321
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):675-83
references.pmid: 17726158
references.citation: Behav Neurosci. 2002 Dec;116(6):989-98
references.pmid: 12492298
references.citation: J Clin Endocrinol Metab. 1997 May;82(5):1332-7
references.pmid: 9141512
references.citation: J Int Assoc Physicians AIDS Care (Chic). 2007 Jun;6(2):95-100
references.pmid: 17538000
references.citation: J Neuroimmunol. 1998 Mar 15;83(1-2):116-23
references.pmid: 9610679
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4005-10
references.pmid: 9108095
references.citation: Drug Alcohol Depend. 2005 Aug 1;79(2):211-23
references.pmid: 16002030
references.citation: Brain Res. 2000 Mar 24;859(2):326-33
references.pmid: 10719081
references.citation: J Neuroimmunol. 2004 Feb;147(1-2):127-30
references.pmid: 14741443
references.citation: AIDS Res Hum Retroviruses. 2011 Jun;27(6):585-92
references.pmid: 20874519
references.citation: Endocrinology. 2012 Mar;153(3):1016-24
references.pmid: 22210740
references.citation: Am J Clin Nutr. 1985 Dec;42(6):1255-65
references.pmid: 3865530
references.citation: Br J Pharmacol. 2008 Jan;153(2):299-308
references.pmid: 17982478
references.citation: Aust N Z J Med. 1988 Feb;18(1):8-15
references.pmid: 3395303
references.citation: J Neuroimmune Pharmacol. 2011 Dec;6(4):516-27
references.pmid: 21830069
references.citation: Psychother Psychosom. 1997;66(4):179-84
references.pmid: 9259040
references.citation: J Pharmacol Exp Ther. 2007 Mar;320(3):1097-105
references.pmid: 17172531
references.citation: Life Sci. 2013 Mar 19;92(8-9):476-81
references.pmid: 22728714
references.citation: Physiol Behav. 1994 Sep;56(3):523-7
references.pmid: 7972403
references.citation: J Clin Invest. 2008 Sep;118(9):3160-9
references.pmid: 18677409
references.citation: Brain Res. 2012 Jan 11;1431:46-52
references.pmid: 22133305
references.citation: Horm Behav. 2010 Jun;58(1):100-10
references.pmid: 19819241
references.citation: J Pain Symptom Manage. 1995 Feb;10(2):89-97
references.pmid: 7730690
references.citation: J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):38-45
references.pmid: 14707790
references.citation: Pharmacol Biochem Behav. 2013 Nov;112:82-8
references.pmid: 24120423
references.citation: Eur J Biochem. 1995 Aug 15;232(1):54-61
references.pmid: 7556170
references.citation: Int Immunopharmacol. 2002 Jan;2(1):69-82
references.pmid: 11789671
references.citation: Pharmacol Biochem Behav. 1991 Nov;40(3):695-700
references.pmid: 1666930
references.citation: J Gen Virol. 2000 Oct;81(Pt 10):2441-2449
references.pmid: 10993932
references.citation: Cancer Causes Control. 2007 May;18(4):391-7
references.pmid: 17235494
references.citation: Adv Exp Med Biol. 1993;335:81-7
references.pmid: 8237612
references.citation: Pharmaceuticals (Basel). 2010 Jun 1;3(6):1873-1886
references.pmid: 20634917
references.citation: J Neurochem. 2011 Sep;118(6):1101-12
references.pmid: 21781118
references.citation: AIDS Res Hum Retroviruses. 2014 Jun;30(6):567-78
references.pmid: 24400995
references.citation: Addict Biol. 2011 Jan;16(1):64-81
references.pmid: 21158010
references.citation: J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):618-26
references.pmid: 23011399
references.citation: Ann Intern Med. 2003 Aug 19;139(4):258-66
references.pmid: 12965981
references.citation: AIDS Patient Care STDS. 2004 Dec;18(12):702-13
references.pmid: 15659881
references.citation: Pharmacol Biochem Behav. 2003 May;75(2):309-18
references.pmid: 12873621
references.citation: Psychopharmacology (Berl). 2003 Nov;170(3):301-308
references.pmid: 12955302
references.citation: Neuroendocrinology. 2009;89(4):424-40
references.pmid: 19136814
references.citation: Eur J Pharmacol. 2001 Oct 26;430(1):41-7
references.pmid: 11698061
references.citation: J Opioid Manag. 2009 May-Jun;5(3):153-68
references.pmid: 19662925
references.citation: Arch Intern Med. 1998 Nov 9;158(20):2257-64
references.pmid: 9818806
references.citation: AIDS Res Hum Retroviruses. 1997 Jun 10;13(9):733-6
references.pmid: 9171216
references.citation: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD005175
references.pmid: 23633327
references.citation: AIDS. 2008 Jan 30;22(3):357-65
references.pmid: 18195562
references.citation: J Neuroimmunol. 2005 Sep;166(1-2):3-18
references.pmid: 16023222
references.citation: Am J Public Health. 2013 Aug;103(8):1457-67
references.pmid: 23763417
references.citation: Eur J Immunol. 2002 Mar;32(3):837-47
references.pmid: 11870628
references.citation: Life Sci. 1994;54(3):159-70
references.pmid: 8289577
references.citation: J Leukoc Biol. 2003 Oct;74(4):486-96
references.pmid: 12960289
references.citation: J Pain Symptom Manage. 2005 Apr;29(4):358-67
references.pmid: 15857739
references.citation: J Pain Symptom Manage. 1997 Jul;14(1):7-14
references.pmid: 9223837
references.citation: Br J Pharmacol. 2010 Jun;160(3):544-8
references.pmid: 20590564
references.citation: Psychoneuroendocrinology. 2010 Sep;35(8):1265-9
references.pmid: 20207489
references.citation: J Gen Virol. 1985 Dec;66 ( Pt 12):2539-49
references.pmid: 2999306
references.citation: J Neuroimmune Pharmacol. 2011 Dec;6(4):540-5
references.pmid: 21484257
references.citation: Exp Clin Psychopharmacol. 2011 Apr;19(2):154-72
references.pmid: 21463073
references.citation: J Pharmacol Exp Ther. 1993 Nov;267(2):635-40
references.pmid: 7504099
references.citation: Neuropsychopharmacology. 2007 Jun;32(6):1391-403
references.pmid: 17091128
references.citation: Behav Pharmacol. 2005 Sep;16(5-6):297-313
references.pmid: 16148436
references.citation: AIDS Patient Care STDS. 2007;21 Suppl 1:S68-76
references.pmid: 17563292
references.citation: Biochem Biophys Res Commun. 2000 Apr 2;270(1):260-6
references.pmid: 10733937